S&P Futures
4,168.25 +21.50 (+0.52%) Dow Futures
32,900.00 +143.00 (+0.44%) Nasdaq Futures
13,317.50 +88.75 (+0.67%) Russell 2000 Futures
1,930.80 +9.00 (+0.47%) Crude Oil
88.05 -0.96 (-1.08%) Gold
1,795.60 +4.40 (+0.25%)
Delcath Systems, Inc. (DCTH)
Chart Events
Performance Outlook
| Previous Close | 4.1600 |
| Open | 4.2110 |
| Bid | 3.8200 x 800 |
| Ask | 0.0000 x 1800 |
| Day's Range | 4.2110 - 4.4003 |
| 52 Week Range | 3.4900 - 11.9520 |
| Volume | |
| Avg. Volume | 31,069 |
| Market Cap | 32.073M |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting
Delcath Systems Inc (NASDAQ: DCTH) announced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system. The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients. The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%. Related:
- Simply Wall St.
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Benzinga
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver
Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research. 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. The Company's PHP system is designed to administer high-dose chemotherapy to the liver
